≡ Menu

Ampyra (dalfampridine): Drug Safety Communication – Seizure Risk for Multiple Sclerosis Patients

A Drug & Medical Device Recall And/Or Safety Alert Has Been Issued: Ampyra (dalfampridine): Drug Safety Communication – Seizure Risk for Multiple Sclerosis Patients. According to the Food & Drug Administration FDA’s MedWatch:

Patients with kidney impairment may develop higher blood levels of the drug, thereby increasing their seizure risk.

For more information on the drug or medical device recall or safety alert, read the Food & Drug Administration’s FDA’s drug or medical device recall or safety alert: Ampyra (dalfampridine): Drug Safety Communication – Seizure Risk for Multiple Sclerosis Patients.

To report an adverse reaction, problem or other issue with a drug or medical device, submit a drug or medical device complaint to the government at fda.gov or MedWatch.

If you have thoughts on the drug or medical device recall or safety alert, share your drug or medical device recall or safety alert comments below.

{ 0 comments… add one }

Leave a Comment